| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PFI-1 | GDSC1000 | pan-cancer | AAC | -0.066 | 0.05 |
| mRNA | Tipifarnib | GDSC1000 | pan-cancer | AAC | -0.07 | 0.05 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.12 | 0.05 |
| mRNA | BRD-K44224150 | CTRPv2 | pan-cancer | AAC | 0.17 | 0.06 |
| mRNA | LY317615 | GDSC1000 | pan-cancer | AAC | -0.067 | 0.06 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | -0.068 | 0.06 |
| mRNA | BI-2536 | GDSC1000 | pan-cancer | AAC | -0.1 | 0.06 |
| mRNA | Obatoclax Mesylate | GDSC1000 | pan-cancer | AAC | -0.065 | 0.06 |
| mRNA | vorinostat:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.071 | 0.06 |
| mRNA | BRD-K26531177 | CTRPv2 | pan-cancer | AAC | -0.07 | 0.07 |